Sistemic announce new miRNA publication exploring the functional differences between MSCs derived from different tissues and the continued expansion of patent portfolio in the exosome and predictive biomarker space.

Release Date: October 5, 2016

Glasgow, Scotland. Sistemic Ltd. announced today that it has recently published, in collaboration with colleagues at Institute of Infection, Inflammation and Immunity, Glasgow Biomedical Research Centre, University of Glasgow, evidence of significant and potentially functionally relevant differences between MSCs from Olfactory Mucosa and from Bone Marrow revealed by miRNA profiling.

Comparative miRNA-Based Fingerprinting Reveals Biological Differences in Human Olfactory Mucosa- and Bone-Marrow-Derived Mesenchymal Stromal Cells.
Lindsay SL, Johnstone SA, McGrath MA, Mallinson D, Barnett SC. 
Stem Cell Reports. 2016; 6(5):729-42

The ability of miRNA profiling to more easily characterise the phenotypic differences is becoming widely accepted and Sistemic, together with many groups around the world, is leading in this exciting field. 

Additionally Sistemic also announced an expansion to its intellectual property portfolio with new patents filed in fields covering predictive use of profiles for a range of applications including patient stratification, donor selection and biological outcome as well as new filings specifically in the use of exosomes as analytical samples. release infographic

Jim Reid, Chairman and CEO stated “these are significant developments for Sistemic. Peer review is critical for the validation of scientific research and this publication supports a wide array of work Sistemic is undertaking assessing the use of miRNAs in phenotypic characterisation of cells and looking at prediction of biological outcome. Additionally we continue to broaden our technology platforms in critical areas including exosome and predictive analytics and see intellectual property as the life-blood of our company.”

Dr. David Mallinson, Vice President of Scientific Operations added “This interesting study with Professor Barnett and colleagues identified miRNA expression differences between MSCs derived from bone marrow and olfactory mucosa. Focussing on two miRNAs, these were then shown to underpin fundamental biological differences between the two MSC types which relate to clinical potential of MSCs derived from olfactory mucosa in the treatment of demyelinating diseases, such as multiple sclerosis. This publication highlights the utility of miRNA in cellular characterization and illustrates the key roles miRNAs play in determining cellular function and phenotype."


Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells (Cell Identity, Purity, Potency, and Safety) as well as monitoring the QC of production. Furthermore, cell products in the later stages of clinical development benefit from SistemQC™ miRNA-based profiling approach in facilitating patient stratification and monitoring the response to the treatment.  In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™. Sistemic has a worldwide customer base and a strong intellectual property portfolio. 

For more information contact: